

This material is an English translation of the press release announced on May 27, 2021 in Japanese, and the Japanese release is given priority about the content and the interpretation.

May 27, 2021

Executive Appointments

Hisamitsu Pharmaceutical Co., Inc. (President and CEO: Kazuhide Nakatomi) has appointed 10 directors (10 reappointments) at the 119th annual general meeting of shareholders held today, and the board of directors said general meeting of shareholders have resolved the appointments of directors and corporate auditors as follows, effective on May 27, 2021.

1. Appointments of directors

[Name]	[Position]	[Title]
Kazuhide Nakatomi	President and CEO	
Kosuke Sugiyama	Senior Managing Director, Executive Officer	Management of Human Resources and R&D
Shinichiro Takao	Managing Director, Executive Officer	Head of BU Division, And Management of Corporate Development, And Management of Public Relations & Investor Relations, And Management of Sustainability Promotion, And President of Hisamitsu U.S. Inc., And Director (part-time) of Yutoku Pharmaceutical Ind. Co. Ltd.
Kyu Saito	Director, Executive Officer	Head of International Division, And Chairman of Hisamitsu America Inc., And President of Hisamitsu Pharmaceutical (Beijing) Technical Consulting Co., Ltd., And President of Hisamitsu Pharmaceutical (China) Co., Ltd., And President of Hisamitsu Pharmaceutical (Hong Kong) Co., Ltd., And Chairman of Hisamitsu Italia S.r.l., And Chairman of Hisamitsu Pharmaceutical Malaysia Sdn. Bhd., And Director of PT. Hisamitsu Pharma Indonesia
Nobuo Tsutsumi	Director, Executive Officer	Head of Legal Department, <u>And Management of Production,</u> And Management of Quality Assurance & Pharmacovigilance, And Management of Compliance, And Director (part-time) of SAGA Hisamitsu Springs Co., Ltd.
Shinichi Murayama	Director, Executive Officer	Management of Internal Audit Division, And Management of Domestic Subsidiary Division, And Outside Corporate Auditor (part-time) of SANOFI-HISAMITSU K.K.
Isao Ichikawa	Outside Director (part-time)	
Teijiro Furukawa	Outside Director (part-time)	

Yuichiro Anzai	Outside Director (part-time)
Tetsugo Matsuo	Outside Director (part-time)

2. Appointments of corporate auditors

[Name]	[Position]
Nobuyuki Nakatomi	Corporate Auditor
Munehiko Hirano	Corporate Auditor
Keinosuke Ono	Outside Corporate Auditor (part-time)
Tetuo Tokunaga	Outside Corporate Auditor (part-time)

3. Appointments of executive officers

[Name]	[Position]	[Title]
Tetsuo Akiyama	Senior Managing Executive Officer	Management of Operation Division, And Chairman of SAGA Hisamitsu Springs Co., Ltd.
Naruhito Higo	Senior Managing Executive Officer	Management of Noven Pharmaceuticals, Inc., And Chairman & CEO of Noven Pharmaceuticals, Inc.
Akira Kayashima	Senior Executive Officer	Management of Volleyball Business Development, And Director of SAGA Hisamitsu Springs Co., Ltd.
Katsuhiko Akiyama	Senior Executive Officer	Management of Licensing, And Management of R&D Division, And Head of MN Business Development Office
Koji Takiyama	Senior Executive Officer	Executive Secretary President's Office, And Head of Olympic & Paralympic Games Tokyo 2020 Promotion Office
Takaaki Terahara	Executive Officer	Head of R&D Division
Hidenao Minami	Executive Officer	Management of External Affairs
(Newly appointed) Masaya Okuno	<u>Executive Officer</u>	Head of Sales & Marketing Division, OTC
(Newly appointed) Mitsutoshi Tsuruta	<u>Executive Officer</u>	Head of Sales & Marketing Division, Ethical Drug
(Newly appointed) Taro Ozaki	<u>Executive Officer</u>	<u>Head of Production Division,</u> <u>And Vice Chairman of Noven Pharmaceuticals,</u> <u>Inc.</u>
(Newly appointed) Sakae Yano	<u>Executive Officer</u>	General Manager of General Affairs Department (Kyushu), BU Division
(Newly appointed) Katsuhiro Sato	<u>Executive Officer</u>	General Manager of APEA Sales Headquarters, International Division, And Singapore Branch Manager, And Manila Branch Manager

Underlined part: new position and title